Safety and tolerability of guadecitabine (SGI-110) plus cisplatin in patients with platinum refractory germ cell tumors (GCT): A phase 1 study

被引：0
|
作者：
Albany, Costantine [1 ]
Hashemi, Neda S. [1 ]
Fang, Fang [2 ]
Lowder, James [3 ]
Einhorn, Lawrence [1 ]
Nephew, Kenneth [2 ]
机构：
[1] Indiana Univ, Indianapolis, IN 46204 USA
[2] Indiana Univ, Bloomington, IN USA
[3] Astex Pharmaceut Inc, Pleasanton, CA USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-1386
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1386
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study
    Pectasides, D
    Pectasides, M
    Farmakis, D
    Aravantinos, G
    Nikolaou, M
    Koumpou, M
    Gaglia, A
    Kostopoulou, V
    Mylonakis, N
    Skarlos, D
    ANNALS OF ONCOLOGY, 2004, 15 (03) : 493 - 497
  • [22] Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors
    G. Varuni Kondagunta
    Jennifer Bacik
    Lawrence Schwartz
    Joel Sheinfeld
    Dean Bajorin
    Jacqueline Vuky
    Stephanie Marion
    Madhu Mazumdar
    George J. Bosl
    Robert J. Motzer
    Investigational New Drugs, 2004, 22 : 177 - 179
  • [23] Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors
    Kondagunta, GV
    Bacik, J
    Schwartz, L
    Sheinfeld, J
    Bajorin, D
    Vuky, J
    Marion, S
    Mazumdar, M
    Bosl, GJ
    Motzer, RJ
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (02) : 177 - 179
  • [24] Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors
    Vuky, J
    McCaffrey, J
    Ginsberg, M
    Mariani, T
    Bajorin, DF
    Bosl, GJ
    Motzer, RJ
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (03) : 265 - 267
  • [25] Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors
    Feldman, Darren R.
    Kondagunta, G. Varuni
    Ginsberg, Michelle S.
    Ishill, Nicole
    Patil, Sujata
    Cestaro, John
    Obbens, Eugenie
    Sheinfeld, Joel
    Bosl, George J.
    Motzer, Robert J.
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (05) : 487 - 490
  • [26] Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors
    Darren R. Feldman
    G. Varuni Kondagunta
    Michelle S. Ginsberg
    Nicole Ishill
    Sujata Patil
    John Cestaro
    Eugenie Obbens
    Joel Sheinfeld
    George J. Bosl
    Robert J. Motzer
    Investigational New Drugs, 2007, 25 : 487 - 490
  • [27] Phase II Trial of Pyrazoloacridine in Patients with Cisplatin-Refractory Germ Cell Tumors
    Jacqueline Vuky
    John McCaffrey
    Michelle Ginsberg
    Tania Mariani
    Dean F. Bajorin
    George J. Bosl
    Robert J. Motzer
    Investigational New Drugs, 2000, 18 : 265 - 267
  • [28] A phase II study assessing the safety and efficacy of ASP1650 in male patients with incurable platinum refractory germ cell tumors
    Adra, Nabil
    Vaughn, David J.
    Einhorn, Lawrence
    Hanna, Nasser H.
    Rosales, Matt
    Arozullah, Ahsan
    Feldman, Darren R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [29] A phase II trial evaluating the efficacy of cabozantinib in the treatment of patients with refractory germ-cell tumors (GCT).
    King, Jennifer
    Dropcho, S.
    Beeler, Sherry
    Sastre, Jessica
    Hanna, Nasser H.
    Einhorn, Lawrence H.
    Adra, Nabil
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [30] PHASE-II STUDY OF IPROPLATIN (CHIP) IN PATIENTS WITH CISPLATIN-REFRACTORY GERM-CELL TUMORS - THE NEED FOR ALTERNATIVE STRATEGIES IN THE INVESTIGATION OF NEW AGENTS IN GCT
    MURPHY, BA
    MOTZER, RJ
    BOSL, GJ
    INVESTIGATIONAL NEW DRUGS, 1992, 10 (04) : 327 - 330
12345